Literature DB >> 11815986

Preradiation chemotherapy for pediatric patients with high-grade glioma.

Johannes E A Wolff1, Astrid K Gnekow, Rolf-Dieter Kortmann, Thorsten Pietsch, Christian Urban, Norbert Graf, Joachim Kühl.   

Abstract

BACKGROUND: To evaluate the feasibility and efficacy of intensive chemotherapy given prior to irradiation in pediatric patients with malignant glioma, the Society of Pediatric Oncology in Germany started a randomized trial in 1991. The high-grade glioma strata had to be closed because of insufficient patient accrual. The follow-up data from these patients are reported.
METHODS: Fifty-two patients with World Health Organization (WHO) Grade 4 malignant glioma (n = 27 patients) or with WHO Grade 3 anaplastic astrocytoma (n = 25 patients) between the ages of 3 years and 17 years were available for analysis. The tumor locations were supratentorial in 42 patients, the cerebellum in 8 patients, and the spinal cord in 2 patients (the brainstem was excluded). Tumor surgeries were biopsy in 10 patients, partial resection in 5 patients, subtotal resection in 10 patients, and macroscopic total resection in 21 patients. Patients received either 54 grays of irradiation (n = 22 patients) followed by chemotherapy with lomustine, vincristine, and cisplatin (maintenance chemotherapy) or sandwich chemotherapy (n = 30 patients), which consisted of ifosfamide, etoposide, methotrexate, cisplatin, and cytosine arabinoside followed by irradiation.
RESULTS: The extent of resection was the most important prognostic factor. The median survival was 5.2 years for patients who underwent tumor resection of > or = 90% compared with 1.3 years for patients who underwent less than complete resection (P < 0.0005). After undergoing macroscopic total resection, sandwich chemotherapy (n = 15 patients) resulted in better overall survival (median, 5.2 years) compared with the maintenance protocol (n = 16 patients; median survival, 1.9 years; P = 0.015). A Cox multivariate regression analysis showed better survival for female patients (P = 0.025), WHO Grade 3 disease (P = 0.016), tumor resection of > or = 90% (P = 0.003), irradiation with > or = 54 grays (P = 0.003), and sandwich chemotherapy (P = 0.006).
CONCLUSIONS: These data suggest that early, intensive chemotherapy increases survival rates in patients with malignant glioma who undergo complete resection. Copyright 2002 American Cancer Society.

Entities:  

Mesh:

Year:  2002        PMID: 11815986     DOI: 10.1002/cncr.10114

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  33 in total

1.  Pediatric supratentorial high-grade glioma: multicenter retrospective observational study of the Korean Society for Pediatric Neuro-Oncology.

Authors:  Tae-Young Jung; Ji Yeoun Lee; Dong-Seok Kim; Hyeon Jin Park; Chae-Yong Kim; Young-Shin Ra; Mee-Jeong Lee; Seong-Ho Kim; Hee-Jo Baek; Il Han Kim; Kyung Duk Park; Seung-Ki Kim
Journal:  J Neurooncol       Date:  2014-11-04       Impact factor: 4.130

2.  Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas.

Authors:  Manila Antonelli; Francesca Romana Buttarelli; Antonietta Arcella; Sumihito Nobusawa; Vittoria Donofrio; Hiroko Oghaki; Felice Giangaspero
Journal:  J Neurooncol       Date:  2010-02-21       Impact factor: 4.130

Review 3.  Pediatric surgical neuro-oncology: current best care practices and strategies.

Authors:  James T Rutka; John S Kuo
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

Review 4.  Pediatric brain tumors: current treatment strategies and future therapeutic approaches.

Authors:  Sabine Mueller; Susan Chang
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

5.  Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children.

Authors:  Alberto Broniscer; Murali Chintagumpala; Maryam Fouladi; Matthew J Krasin; Mehmet Kocak; Daniel C Bowers; Lisa C Iacono; Thomas E Merchant; Clinton F Stewart; Peter J Houghton; Larry E Kun; Davonna Ledet; Amar Gajjar
Journal:  J Neurooncol       Date:  2006-02       Impact factor: 4.130

Review 6.  Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies.

Authors:  Trent R Hummel; Lionel M Chow; Maryam Fouladi; David Franz
Journal:  Paediatr Drugs       Date:  2013-02       Impact factor: 3.022

Review 7.  Chemotherapy for malignant brain tumors of childhood.

Authors:  Nicholas G Gottardo; Amar Gajjar
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

8.  A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study.

Authors:  Darren Hargrave; Birgit Geoerger; Didier Frappaz; Torsten Pietsch; Lyle Gesner; Laura Cisar; Aurora Breazna; Andrew Dorman; Ofelia Cruz-Martinez; Jose Luis Fuster; Xavier Rialland; Céline Icher; Pierre Leblond; David Ashley; Giorgio Perilongo; Martin Elliott; Martin English; Niels Clausen; Jacques Grill
Journal:  J Neurooncol       Date:  2013-03-04       Impact factor: 4.130

9.  Histone acetylation resulting in resistance to methotrexate in choroid plexus cells.

Authors:  Preethi Prasad; Hernan Vasquez; Chandra M Das; Vidya Gopalakrishnan; Johannes E A Wolff
Journal:  J Neurooncol       Date:  2008-10-14       Impact factor: 4.130

10.  Subpopulations of malignant gliomas in pediatric patients: analysis of the HIT-GBM database.

Authors:  Johannes E A Wolff; Carl Friedrich Classen; Sabine Wagner; Rolf-Dieter Kortmann; Shana L Palla; Torsten Pietsch; Joachim Kühl; Astrid Gnekow; Christof M Kramm
Journal:  J Neurooncol       Date:  2008-01-22       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.